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Abstract
Increasing the understanding of the impact of changes in oncogenes and tumor suppressor genes is essential for
improving the management of lung cancer. Recently, we identified a new mouse lung–specific tumor suppressor—
the G protein–coupled receptor 5A (Gprc5a). Microarray analysis of the transcriptomes of lung epithelial cells cultured
from normal tracheas ofGprc5a knockout andwild-typemice defined a loss-of-Gprc5a gene signature, which revealed
many aberrations in cancer-associated pathways. To assess the relevance of this mouse tumor suppressor to human
lung cancer, the loss-of-Gprc5a signaturewas cross species comparedwith and integratedwith publicly available gene
expression data of human normal lung tissue and non–small cell lung cancers. The loss-of-Gprc5a signature was prev-
alent in human lung adenocarcinomas compared with squamous cell carcinomas or normal lung. Furthermore, it iden-
tified subsets of lung adenocarcinomaswith poor outcome. These results demonstrate that gene expression patterns
of Gprc5a loss in nontumorigenic mouse lung epithelial cells are evolutionarily conserved and important in human
lung adenocarcinomas.
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Introduction
The identification of new effective biomarkers will undoubtedly
improve clinical management of lung cancer and is tightly linked to
a better understanding of the molecular events associated with the
development and progression of the disease [1,2]. Both genetic and epi-
genetic aberrations in oncogenes and tumor suppressor genes have been
implicated in lung cancer etiology. Such changes include mutations in
KRAS [3], amplification of the epidermal growth factor receptor
(EGFR) [4], and its mutation in adenocarcinomas [5,6], mutations
in the tumor suppressor p53 [5], and epigenetic silencing of retinoic
acid receptor beta (RARβ) [7]. We have previously identified a novel
retinoic acid–regulated gene, mGprc5a/hGPRC5A, which is preferen-
tially expressed in mouse and human normal lungs [8]. Earlier attempts
at specific targeting of Gprc5a expression in mouse lung have shown
that there are no significant developmental defects and that epithelial
cell differentiation is normal, and lung structure is intact after lung-
specific knockout of the gene and follow-up from early embryonal
stages up to 3 months [9]. More recently, our group showed that
Gprc5a knockout mice (Gprc5a−/−), when followed up to 2 years, de-
velop spontaneous lung adenocarcinomas at age 12 months and on-
ward, indicating that this gene is a lung-specific tumor suppressor
[10]. Moreover, in the same study by our group, the expression of
human GPRC5A messenger RNA (mRNA) was analyzed in a publicly
available microarray data set and was found to be significantly lower in
human lung adenocarcinomas and squamous cell carcinomas (SCCs)
relative to normal lung [10].
Genome-wide expression profiling approach has been proven to be
a useful method for the discovery of novel cancer subclasses [11–13].
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Moreover, comparative genomics by directly comparing expression
profiles of experimental mouse models and corresponding human dis-
eases has highlighted conserved expression signatures and networks
important for the phenotype under study [14–16]. Therefore, we sur-
mised that information obtained from studying gene expression in the
Gprc5a knockout mouse model could help us to begin to understand
the molecular consequences of Gprc5a loss that may subsequently pro-
vide new insights into human lung cancer expression patterns.
Materials and Methods
WT-NLE and NULL-NLE Normal Epithelial Cells
The Gprc5a knockout mouse was generated previously in our labo-
ratory [10]. Normal lung epithelial cells, WT-NLE and NULL-NLE,
were derived from tracheas of mice (C57Bl/6 × 129sv) F1 with wild-
type Gprc5a and mice lacking Gprc5a (knockout), respectively. Briefly,
tracheas were dissected from 3-week-old Gprc5a WT and Gprc5a
knockout mice and were cut into small pieces, which were incubated
in a tissue-dissociating solution ACCUMAX from Innovative Cell
Technologies (San Diego, CA). The dissociated cells and tissue frag-
ments were then transferred to PRIMARIA tissue culture dishes (BD
Biosciences, San Jose, CA) and incubated in AmnioMAX-C100 basal
medium (GIBCO, Invitrogen, Grand Island, NY). The epithelial cells
were detached by trypsinization, subcultured, and grown in keratino-
cyte serum-free medium (GIBCO, Invitrogen). The cell lines were
karyotyped by G banding in the MD Anderson Institutional Molecular
Cytogenetics Facility and were found to be of mouse origin.
RNA Extraction
Total RNAwas isolated and purified using RNeasy columns (Qiagen,
Valencia, CA). The cells were washed twice with ice-cold PBS, lysed
and incubated with DNase I for RNA isolation according to the manu-
facturer’s instructions. RNA quality based on the 28S/18S ribosomal
RNA ratio (>1.5) was assessed using the RNA 6000 Nano Lab-On-
chip and Agilent 2100 Bioanalyzer device (Agilent Technologies, Palo
Alto, CA).
Microarray Sample Preparation, Hybridization, and Scanning
Synthesis of double-stranded complementary DNA was performed
using the Superscript Choice system (Invitrogen) using 5 μg of total
RNA for each strand. Biotin-labeled complementary RNAwere synthe-
sized by in vitro transcription reaction using the ENZOBioArray High-
Yield RNA transcript labeling kit (Affymetrix, Santa Clara, CA).
Fragmented complementary RNA were then hybridized to GeneChip
Mouse Genome 430 2.0 arrays (Affymetrix) according to the manufac-
turer’s instructions. The arrays were scanned with a GeneChip Scanner
3000 from Affymetrix, and raw image files were converted to probe set
data (*.CEL files), using the Affymetrix GeneChip Operating Software.
Expressionmicroarray data have been submitted to the National Center
for Biotechnology Information’s Gene Expression Omnibus repository
and are MIAME-compliant.
Derivation of a Loss-of-Gprc5a Signature
Raw microarray data files (*.CEL) were imported and analyzed using
the BRB-ArrayTools v.3.7.0 developed byDr. Richard Simon and BRB-
ArrayTools Development Team [17]. Robust multiarray analysis [18]
was used for normalization of gene expression data in R language envi-
ronment. Differentially expressed gene features in the loss-of-Gprc5a
signature were selected based on the criteria of P < .001 of a random
variance t test with permutation and estimation of the false discovery
rate and a two-fold difference in expression. The loss-of-Gprc5a signa-
ture was also analyzed using ingenuity pathways analysis (IPA; http://
www.ingenuity.com) for functional pathways analysis.
Cross-species Analysis and Survival Analysis
To assess the expression of the loss-of-Gprc5a signature in human
non–small cell lung cancer (NSCLC) compared with normal lung, we
integrated unique orthologous members of the mouse gene signature
with expression data from the data sets by Su et al. (27 lung adenocar-
cinomas and paired adjacent normal lung) [19] and Stearman et al. (20
lung adenocarcinomas and 19 adjacent normal lung; from 10 patients
in replicate) [20]. To evaluate the clinical relevance of the mouse loss-of-
Gprc5a signature in human lung cancer, we used available human
NSCLCmicroarray data sets from the studies by Shedden et al. (National
Cancer Institute Director’s Challenge, 442 lung adenocarcinomas;
https://caarraydb.nci.nih.gov/caarray) [21], Bild et al. (Duke cohort,
58 adenocarcinomas and 53 SCCs; http://data.cgt.duke.edu/oncogene.
php) [22], and Bhattacharjee et al. (Harvard cohort, 125 adenocar-
cinomas) [12]. Raw microarray data from all data sets were analyzed
and normalized using the BRB-ArrayTools. Before integration of the
mouse loss-of-Gprc5a signature with the human lung cancer data sets,
unique orthologous genes present in both murine (Affymetrix Gene-
Chip Mouse Genome 430 2.0) and human (Affymetrix HG-U95A,
HG-U95Av2, HG-U133A and HG-U133 plus 2.0) platforms were
identified using NetAffx from Affymetrix (http://www.affymetrix.
com/analysis/index.affx). Before integration of the mouse and human
orthologous gene expression data into mixed mouse-human data sets,
gene expression data were median-centered independently [15]. Hier-
archical cluster analysis by average linkage was performed with Cluster
2.11, and results were visualized with TreeView programs (Michael
Eisen Laboratory, http://rana.lbl.gov/EisenSoftware.htm). Kaplan-
Meier and log-rank test survival analyses while censoring for patients
and based on Gprc5a-WT and-NULL clusters after hierarchical clus-
tering analysis were performed using the R language environment
v2.8.0 (http://www.r-project.org/).
To predict class, we adopted a previously developed model using
six algorithms, namely, compound covariate predictor, linear discrimi-
nator analysis, nearest neighbors 1 and 3, nearest centroid, and sup-
port vector machine [15]. Lung adenocarcinomas from the study of
Shedden et al. were used as a training set (n = 442), and adenocar-
cinomas from the Duke and Harvard cohorts were pooled as a test
set (n = 183; DH cohort). An optimized classifier list was generated
using a leave-one-out cross-validation approach. The six classification
algorithms were then applied to the test set, and survival analysis was
performed to assess the clinical significance of predicted Gprc5a-WT
and Gprc5a-NULL groups by Kaplan-Meier survival analyses while
censoring for patients and log-rank tests in R language environment.
Results
Biological Characteristics of a Mouse Loss-of-Gprc5a Gene
Signature in Lung Epithelial Cells Derived from Gprc5a
Knockout Mice
We performed global gene expression analysis on the transcriptome
of NLE cells isolated from Gprc5a wild-type and knockout mice,
WT-NLE and NULL-NLE cells, respectively (Figure 1A) to under-
stand potential molecular consequences of the loss of Gprc5a. A gene
expression signature reflecting the loss of Gprc5a was found to be
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composed of 1586 gene features differentially expressed between these
cells based on selection criteria of P < .001 of the univariate t test and a
difference in expression by at least two-fold (Figure 1B). Functional anal-
ysis using IPA revealed the significant modulation of canonical cancer–
related gene sets and pathways, such as cell death, cell growth and
proliferation, cell cycle, growth factor and receptor signaling, survival,
inflammation, tumor suppressor p53 signaling, andWnt/β-catenin sig-
naling pathways (all P < .001; Figure 1,C andD, and TableW1).More-
over, Gprc5a knockout cells displayed increased activation (marked
by the red arrow) of oncogenic biological processes and pathways such
as cell growth and proliferation, cell cycle, inflammation, and Wnt/β-
catenin signaling pathway compared with wild-type cells (Figure 1, C
and D). In addition, deactivation or inhibition (marked by blue arrow)
of tumor-suppressive biological functions and pathways such as cell
death, p53 signaling, and the G2/M cell cycle–controlling checkpoint
was evident in the Gprc5a knockout cells (Figure 1, C and D). These
results indicate that loss of Gprc5a in lung epithelial cells perturbs ex-
pression of genes strongly associated with cancer and important in
mouse lung carcinogenesis.
Mouse Loss-of-Gprc5a Gene Signature Discriminates Human
Lung Adenocarcinomas from Adjacent Normal Tissues
The association of Gprc5a loss with canonical cancer–related path-
ways prompted us to address the biological relevance of the loss-of-
Gprc5a signature to human NSCLC. By using only orthologous genes
present in both mouse and human microarray platforms, we first in-
tegrated the loss-of-Gprc5a expression signature with gene expression
data of human lung adenocarcinomas and adjacent normal counter-
parts available from previous studies [19,20]. Hierarchical clustering
and principal component analyses of the integrated data revealed that
the mouse loss-of-Gprc5a signature was tightly clustered and associated
with human lung adenocarcinomas relative to normal lung (Figures 2,
A and B, and W1, A and B). In addition, expression of GPRC5A was
Figure 1. Derivation of amouse loss-of-Gprc5a signature. (A) Normal epithelial cells cultured from tracheas ofGprc5awild-type and knockout
mice (WT-NLE andNULL-NLE, respectively)were used for global gene expression analysis to understandmolecular consequencesofGprc5a
loss. (B) A mouse loss-of-Gprc5a gene signature encompassing 1586 gene features was derived based on selection criteria described in
the Materials and methods section. (C and D) Functional analyses of the mouse loss-of-Gprc5a signature using global functional categories
from IPA. The value of−log(significance) represents the inverse log of theP values of themodulation of the depicted functional categories (C)
and pathways (D) between theWT-NLE andNULL-NLE cells. The number of genes displayingmore than a two-fold change is indicated above
each bar. Red arrows indicate the predicted activation of the biological processes and pathways by IPA,whereas the blue arrows indicate the
predicted inhibition of the processes and pathways (C and D). *Blue arrow signifies predicted inhibition of the G2/M cell cycle checkpoint
despite the predicted activation of the DNA damage pathway by IPA.
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significantly lower in lung adenocarcinomas than in adjacent normal
tissues in both human data sets (Figure 2C ).
Mouse Loss-of-Gprc5a Signature Is Significantly Associated
with Human Lung Adenocarcinomas than with SCCs
The mouse loss-of-Gprc5a expression signature was also integrated
with human gene expression data containing 58 lung adenocarcinomas
and 53 SCCs available from the study by Bild et al. (Duke cohort) [22].
In the hierarchical cluster analysis of the composite data, 51 of 58
adenocarcinomas coclustered with the loss-of-Gprc5a signature, whereas
43 of 53 SCCs samples were in the Gprc5a-WT cluster (Figure 2D and
Table W2; P = 2.8 × 10−13 of the χ 2 test). The closer association of the
mouse loss-of-Gprc5a signature with lung adenocarcinomas rather
than SCCs was also evident in themultidimensional space (Figure 2E ).
Figure 2. The mouse loss-of-Gprc5a signature differentiates human lung adenocarcinomas from normal lung or SCCs. Dendrograms of
hierarchical cluster analysis of mixed mouse-human data sets including lung adenocarcinomas and adjacent normal lung samples from
the studies by Stearman et al. (A) and Su et al. (B) as well as the WT-NLE and NULL-NLE mouse cells. Normalized GPRC5A expression in
the integrated data is represented in the single row under the dendrograms as red (high) or green (low) and is quantified in the human
normal lung and adenocarcinomas (C); P values were obtained by the Student’s t test. Human orthologs of the mouse loss-of-Gprc5a
signature were integrated with data of human NSCLC samples from the study by Bild et al. and analyzed by hierarchical cluster analysis
after filtering and retaining of genes with a fold change of at least two from the median in at least 12 patient samples (D) and by principal
component analysis (E). (F) Log-rank statistics and Kaplan-Meier plots were used to assess for the OS of lung adenocarcinoma patients
and SCC patients separated independently according to clustering patterns (blue, Gprc5a-WT cluster; red, Gprc5a-NULL cluster). The
number of censored patients of total number of cluster patients is indicated between the parentheses next to the survival plot arms.
502 Loss-of-Gprc5a Signature in Lung Adenocarcinoma Kadara et al. Neoplasia Vol. 12, No. 6, 2010
We next explored the possibility that the loss-of-Gprc5a signature ex-
hibits prognostic properties in human lung adenocarcinoma. The 58
lung adenocarcinomas patients were dichotomized on the basis of their
similarity of gene expression to the loss-of-Gprc5a signature after hierar-
chical clustering alone and independent of the SCC samples (clustering
heat maps not shown). Lung adenocarcinoma patients who expressed
the loss-of-Gprc5a signature exhibited a significantly worse overall sur-
vival (OS) when compared with those who did not express the signature
(P = .02 of the log-rank test; Figure 2F, left). Conversely, when the
mouse loss-of-Gprc5a signature was integrated with human lung SCCs
only, no significant differences in OS were found (P = .3 of the log-rank
test; Figure 2F, right) between the cluster of SCC patients expressing the
signature (NULL cluster) and the cluster that did not (WT cluster) after
hierarchical cluster analysis (heat map not shown).
The expression of the mouse loss-of-Gprc5a gene signature was then
assessed in a larger cohort of human lung adenocarcinomas, the NCI
Director’s Challenge study [21]. After hierarchical cluster analysis of
the integrated data (Figure 3A), patients expressing the loss-of-Gprc5a
gene signature displayed worse OS (P = .00003) than those lacking the
signature (Figure 3B). To validate the association of loss-of-Gprc5a
signature with poor survival, the NCI Director’s Challenge data sets
were used as a training set (n = 442), and gene expression data of ade-
nocarcinomas from the Duke [22] and Harvard [12] cohorts (n = 183)
were pooled as a validation set (DH cohort). The number of genes was
optimized to minimize misclassification during a leave-one-out cross-
validation approach (Figure 3C and Table 1). Various prediction algo-
rithms showed that the OS of human lung adenocarcinoma patients in
the DH validation cohort predicted to harbor the mouse loss-of-Gprc5a
Figure 3. The mouse loss-of-Gprc5a gene signature is associated with poor survival in human lung adenocarcinoma. (A) The mouse loss-of-
Gprc5a gene signature was integrated with and analyzed in the NCI Director’s Challenge data sets (n= 748) by hierarchical cluster analysis
after filtering and retaining of geneswith a fold change of at least two from themedian in at least eight patient samples. (B) Kaplan-Meier plot
for the OS of lung adenocarcinoma patients separated according to clustering patterns (blue,Gprc5a-WT cluster; red,Gprc5a-NULL cluster).
(C) Humanorthologs of the loss-of-Gprc5a signature andpresent in all array platformsof the studiesbyShedden et al., Bild et al. (Duke cohort),
and Bhattacharjee et al. (Harvard cohort) were identified (n= 547). Lung adenocarcinomas from the NCI Director’s Challengewere used as a
training set (n=442), and those from theDuke andHarvard cohortswere pooled as a validation set (DH cohort). (D) Kaplan-Meier plots for the
survival of lung adenocarcinoma patients clustered intoGprc5a-WT cluster (blue) orGprc5a-NULL cluster (red) as predicted by the prediction
algorithms. The number of censored patients of the total number of cluster patients is indicated between the parentheses next to the survival
plot arms.CCP indicates compound covariate predictor; LDA, linear discriminator analysis; LOOCV, leave-one-out cross-validation;NC, near-
est centroid; NN-1/-3, nearest neighbors 1 and 3; SVM, support vector machine.
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signature was significantly poorer than that of patients predicted to lack
the signature (Figure 3D).
Discussion
Pathway signatures representing aberrant activation of oncogenes or
inactivation of tumor suppressor genes have provided important in-
sights into lung cancer development [23]. Having recently identified
a new mouse lung tumor suppressor gene (Gprc5a) [10], we surmised
that characterization of the differential gene expression patterns of epi-
thelial cells isolated from lungs of Gprc5a wild-type and knockout mice
will improve the understanding of the molecular characteristics of loss
of Gprc5a during the development of lung cancer. The results of this
comparison have led to the derivation of a mouse loss-of-Gprc5a gene
signature. This signature suggested that loss of Gprc5a is well associ-
ated with cancer-related molecular processes and pathways, including
growth factor and receptor signaling, cell death, cell cycle, survival,
cell growth and proliferation, and inflammation. The large variety of
genes and pathways affected by the loss of Gprc5a expression attests
to the pivotal role that this lung-specific tumor suppressor plays in
mouse lung carcinogenesis.
We then hypothesized that the mouse loss-of-Gprc5a signature
could be valuable in improving the understanding of differential gene
expression patterns related to human lung carcinogenesis. This hypoth-
esis is based in part on the assertion that conserved gene expression
signatures resembling similar phenotypes in different species are func-
tionally important for the specific phenotype [24]. Using comparative
functional genomic approaches and integrating the mouse loss-of-
Gprc5a signature with published human lung (normal and malignant)
gene expression data, we found that the signature is 1) highly conserved
in humanNSCLC and sufficient for discriminating human lung adeno-
carcinomas from adjacent normal lung tissues, 2) better associated with
gene expression patterns of lung adenocarcinomas than of SCCs, and 3)
associatedwith poor prognosis of human lung adenocarcinoma patients.
We previously demonstrated by in silico analysis in a published data
set by Bhattacharjee et al. [12] that GPRC5A mRNA is significantly
decreased in lung adenocarcinomas, SCCs, carcinomas, and bronchio-
alveolar carcinomas compared with normal lung, suggesting that
GPRC5A loss of expression is not cell lineage–specific. Importantly, both
the Gprc5a knockout (NULL) and wild-type cells (WT), from which
the loss-of-Gprc5a signature was derived, had been isolated from trachea
of 3-month-old Gprc5a knockout and wild-type mice, respectively, and
because we used the exact same isolation and culture conditions, we as-
sume that the cells are from the same lineage. Therefore, we thought it
was justifiable to integrate and cross species analyze the loss-of-Gprc5a
signature in the normal mouse cells with both adenocarcinomas and
SCCs. Although the signature is based on differences between epithelial
cells derived from normal tracheas of wild-type and Gprc5a knockout
mice, it was prevalent in human lung adenocarcinomas that develop
from small airways in the lung periphery rather than SCCs that are
derived from bronchial upper airway epithelial cells. It is unclear why,
despite decreased GPRC5AmRNA levels in both subtypes of NSCLC,
gene expression patterns downstream of Gprc5a loss are more relevant
to human lung adenocarcinomas rather than to SCCs. The reason may
be that Gprc5a knockout mice develop adenomas and adenocarcino-
mas and not SCCs [10]. Interestingly, Hassan et al. [25] recently dem-
onstrated that an embryonic stem cell–like signature identified poorly
differentiated lung adenocarcinoma with dismal prognosis but was
not relevant for SCCs, suggesting that biological pathway–specific gene
signatures may be differentially expressed and relevant in different sub-
types of NSCLC.
We have previously analyzed publicly available transcriptome data
that have indicated statistically significant decreases in mRNA levels
of GPRC5A in adenocarcinoma (n = 139) and SCC (n = 21) compared
with normal lung (n = 17) [10]. We do not know the mechanism of
the decrease in GPRC5A expression, but it cannot be accounted for
by gene loss because the frequency of chromosome 12p12.3 loss is
low in NSCLC tumors. The expression is likely silenced by epigenetic
mechanisms because we found that GPRC5A can be reexpressed
after treatment of lung cancer cell lines with histone deacetylase in-
hibitors (unpublished observations). Interestingly, no mutations had
been identified in the GPRC5A gene in samples from 44 human can-
cers (22 breast tumors, 11 colorectal tumors, and 11 glioblastomas)
[26,27] as well as in 20 human NSCLC cell lines we have analyzed (un-
published observations).
In conclusion, we demonstrated the molecular similarity of the
Gprc5a knockout mouse model to its human counterpart, indicating
that it recapitulates fundamental features of human lung adenocarci-
noma. Our study strongly suggests that loss ofGprc5a in the lung might
influence the clinical outcome of lung adenocarcinoma. Thus, gene
expression patterns associated with loss of Gprc5a would be valuable
for the identification of novel biomarkers and targets for intervention.
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Table W1. Significantly Modulated Gene Ontology Sets between Gprc5a-Knockout and Wild-type Lung Epithelial Cells.
GO Term No. Genes P
LS KS GSA Test
Negative regulation of signal transduction 6 .00001 .0007322 <.005
Methyltransferase activity 5 .00001 .0058048 .23
Positive regulation of small GTPase mediated signal transduction 6 .00001 .0003788 .15
Regulation of multicellular organismal process 28 .00001 .000301 .18
Innate immune response 11 .00001 .00001 .15
Transferase activity, transferring one-carbon groups 5 .00001 .0058048 .23
Positive regulation of multicellular organismal process 13 .0000974 .0000924 .34
Inflammatory response 21 .0006349 .0178738 .15
Defense response 35 .0006397 .0604121 .3
Regulation of immune system process 9 .0008315 .0001589 .29
Positive regulation of immune system process 9 .0008315 .0001589 .29
Oxidoreductase activity 92 .000967 .0053086 .04
Oxidoreductase activity, oxidizing metal ions 8 .0012144 .00128 <.005
Response to stress 63 .0012605 .0230982 .32
Immune response 39 .0014611 .0657758 .15
Oxidoreductase activity, acting on the CH–CH group of donors 6 .0015423 .0013885 .27
Activation of immune response 6 .001687 .0014489 .14
Regulation of immune response 8 .0023036 .0017339 .29
Positive regulation of immune response 8 .0023036 .0017339 .29
Leukocyte-mediated immunity 7 .0023494 .002228 .1
Lymphocyte-mediated immunity 7 .0023494 .002228 .1
Immune effector process 7 .0023494 .002228 .1
Response to chemical stimulus 35 .0024562 .028446 .1
Regulation of cell size 10 .003463 .0037458 <.005
Regulation of cell growth 10 .003463 .0037458 <.005
Cell growth 10 .003463 .0037458 <.005
G protein–coupled receptor binding 7 .003494 .0032609 .15
Chemokine receptor binding 7 .003494 .0032609 .15
Regulation of growth 16 .0035601 .0159644 <.005
Oxidoreductase activity, oxidizing metal ions, oxygen as acceptor 6 .0035804 .002443 <.005
Calcium ion homeostasis 8 .0036095 .0030806 <.005
Cellular calcium ion homeostasis 8 .0036095 .0030806 <.005
Cofactor metabolic process 16 .0036246 .0892564 .29
Hydrolase activity, acting on ester bonds 55 .0041281 .0324188 .32
Endopeptidase inhibitor activity 25 .0044359 .0039886 .04
Protease inhibitor activity 25 .0044359 .0039886 .04
Response to external stimulus 40 .0048794 .0077369 .15
Proteolysis 50 .0049521 .0151898 .07
Oxidoreductase activity, acting on the CH–OH group of donors, NAD or NAD 14 .0055272 .001675 <.005
Cysteine-type endopeptidase activity 11 .0059417 .0599941 <.005
Microtubule-organizing center 5 .0072669 .0073931 <.005
Tubulin binding 5 .0072669 .0073931 <.005
Acute inflammatory response 6 .0087036 .0033099 .15
Hematopoietin/interferon class (D200 domain) cytokine receptor binding 5 .0088543 .0089969 <.005
Positive regulation of mononuclear cell proliferation 5 .0088543 .0089969 <.005
Positive regulation of lymphocyte proliferation 5 .0088543 .0089969 <.005
Cysteine-type peptidase activity 13 .0097421 .0480694 <.005
Positive regulation of B-cell activation 5 .0130992 .0126038 <.005
Metal ion homeostasis 9 .0147123 .0174354 <.005
Cellular metal ion homeostasis 9 .0147123 .0174354 <.005
Regulation of lymphocyte activation 9 .0187656 .0035468 <.005
Regulation of cell activation 9 .0187656 .0035468 <.005
Oxidoreductase activity, acting on CH–OH group of donors 15 .0214959 .0194171 <.005
Gliogenesis 13 .0244059 .0409053 <.005
Apoptosis 73 .0280493 .1708852 <.005
Mononuclear cell proliferation 6 .0325799 .0202514 <.005
Regulation of mononuclear cell proliferation 6 .0325799 .0202514 <.005
Regulation of lymphocyte proliferation 6 .0325799 .0202514 <.005
Lymphocyte proliferation 6 .0325799 .0202514 <.005
Cell recognition 5 .0329337 .0413222 <.005
Cell death 75 .0345939 .2052998 <.005
Programmed cell death 75 .0345939 .2052998 <.005
Death 75 .0345939 .2052998 <.005
Myosin binding 5 .0357922 .0303043 <.005
B-cell activation 6 .0369608 .0202514 <.005
Regulation of B-cell activation 6 .0369608 .0202514 <.005
Growth 31 .045208 .2559096 <.005
B-cell proliferation 5 .0483287 .0657513 <.005
Regulation of B-cell proliferation 5 .0483287 .0657513 <.005
Growth factor binding 6 .0488795 .0240172 <.005
Regulation of T-cell activation 6 .0834344 .0202514 <.005
T-cell activation 12 .1049736 .2287792 <.005
Table W1. (continued )
GO Term No. Genes P
LS KS GSA Test
Regulation of biological quality 38 .1148766 .0967393 <.005
Endoplasmic reticulum 44 .1396441 .4255679 <.005
Structural molecule activity 52 .1593635 .0004691 <.005
Odontogenesis (sensu Vertebrata) 14 .1684862 .2972718 <.005
Odontogenesis 14 .1684862 .2972718 <.005
Homeostatic process 29 .1914248 .1491862 <.005
Enzyme-linked receptor protein signaling pathway 49 .1945213 .3315078 <.005
Transmembrane receptor protein tyrosine kinase signaling pathway 34 .1955935 .3321729 <.005
Monocarboxylic acid metabolic process 31 .2294794 .044724 <.005
Vacuole 14 .2302419 .4236341 <.005
BMP signaling pathway 9 .3146698 .432143 <.005
Glycosaminoglycan binding 15 .3173276 .5017923 <.005
Cell-cell adhesion 36 .3571724 .138097 <.005
Fatty acid metabolic process 19 .37593 .0531365 <.005
Lytic vacuole 12 .3844111 .5239573 <.005
Transmembrane receptor protein serine/threonine kinase signaling pathway 15 .3920316 .5344075 <.005
Pattern binding 16 .4419784 .6637115 <.005
Polysaccharide binding 16 .4419784 .6637115 <.005
Carbohydrate binding 30 .5302077 .4032964 <.005
Cellular structure morphogenesis 69 .6747371 .3197544 <.005
Cell morphogenesis 69 .6747371 .3197544 <.005
Regulation of anatomical structure morphogenesis 5 .6915955 .8003922 <.005
Regulation of cell morphogenesis 5 .6915955 .8003922 <.005
JNK cascade 9 .715804 .9063296 <.005
Stress-activated protein kinase signaling pathway 9 .715804 .9063296 <.005
Cellular macromolecule catabolic process 11 .8145988 .8057409 <.005
GTPase regulator activity 20 .8505053 .9217671 <.005
Hair follicle development 8 .8861753 .7807329 <.005
Molting cycle 8 .8861753 .7807329 <.005
Molting cycle process 8 .8861753 .7807329 <.005
Hair cycle process 8 .8861753 .7807329 <.005
Hair cycle 8 .8861753 .7807329 <.005
Wnt receptor signaling pathway 18 .8925935 .5528784 <.005
Transferase activity, transferring phosphorus-containing groups 88 .9138415 .9203534 <.005
Negative regulation of transferase activity 11 .9333491 .9688947 <.005
Negative regulation of protein kinase activity 11 .9333491 .9688947 <.005
MAPKKK cascade 17 .943078 .9879397 <.005
Negative regulation of enzyme activity 12 .946406 .9804483 <.005
Gene ontology sets were chosen based on significance of a P < .005 in at least one of three statistical tests; LS/KS permutations and Efron-Tibshirani's Gene Set Analysis (GSA) using the max-mean test.
Figure W1. The mouse loss-of-Gprc5a gene signature distinguishes human lung adenocarcinoma from adjacent normal lung. Human
orthologs of the loss-of-Gprc5a-gene signature and found in the studies by Stearman et al. (A) and Su et al. (B) were integrated with and
analyzed in the gene expression data of both studies as described in Figure 2. Principal component analysis was then performed on
each mixed mouse-human data set using metric centered correlation.
Table W2. Sensitivity and Specificity for Discriminating Lung Adenocarcinoma from SCC by the
Mouse Loss-of-Gpcr5a Gene Signature.
Cluster SCC Adenocarcinoma
WT 43 7
NULL 10 51
P value by χ 2 test = 2.8 × 10−13.
Sensitivity = 0.88.
Specificity = 0.81.
